Jason Raleigh Nunn Buys 63,158 Shares of Zenas BioPharma (NASDAQ:ZBIO) Stock

Zenas BioPharma, Inc. (NASDAQ:ZBIOGet Free Report) Director Jason Raleigh Nunn bought 63,158 shares of the stock in a transaction dated Thursday, October 9th. The stock was purchased at an average cost of $19.00 per share, for a total transaction of $1,200,002.00. Following the acquisition, the director owned 1,173,395 shares in the company, valued at $22,294,505. The trade was a 5.69% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Zenas BioPharma Stock Up 4.4%

Shares of NASDAQ ZBIO opened at $26.99 on Thursday. The firm’s 50-day simple moving average is $19.48 and its 200 day simple moving average is $13.74. The company has a market cap of $1.14 billion and a price-to-earnings ratio of -7.60. Zenas BioPharma, Inc. has a 12-month low of $5.83 and a 12-month high of $29.73.

Zenas BioPharma (NASDAQ:ZBIOGet Free Report) last issued its quarterly earnings results on Tuesday, August 12th. The company reported ($1.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.02) by ($0.23).

Institutional Trading of Zenas BioPharma

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Federated Hermes Inc. increased its stake in shares of Zenas BioPharma by 60.8% in the 2nd quarter. Federated Hermes Inc. now owns 1,861,838 shares of the company’s stock valued at $18,041,000 after acquiring an additional 703,838 shares during the last quarter. Geode Capital Management LLC increased its stake in shares of Zenas BioPharma by 4.6% in the 2nd quarter. Geode Capital Management LLC now owns 373,617 shares of the company’s stock valued at $3,621,000 after acquiring an additional 16,461 shares during the last quarter. Jefferies Financial Group Inc. bought a new stake in shares of Zenas BioPharma in the 1st quarter valued at about $348,000. Nuveen LLC bought a new stake in shares of Zenas BioPharma in the 1st quarter valued at about $250,000. Finally, Rhumbline Advisers increased its stake in Zenas BioPharma by 71.3% during the 2nd quarter. Rhumbline Advisers now owns 19,721 shares of the company’s stock worth $191,000 after purchasing an additional 8,207 shares in the last quarter.

Wall Street Analyst Weigh In

ZBIO has been the topic of several research reports. Wedbush upped their price target on shares of Zenas BioPharma from $35.00 to $40.00 and gave the stock an “outperform” rating in a research report on Thursday, October 9th. HC Wainwright restated a “buy” rating and set a $30.00 target price on shares of Zenas BioPharma in a research report on Thursday, October 9th. Wall Street Zen downgraded shares of Zenas BioPharma from a “hold” rating to a “sell” rating in a research report on Friday, September 26th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Zenas BioPharma in a research report on Wednesday, October 8th. Three investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Zenas BioPharma presently has a consensus rating of “Moderate Buy” and a consensus target price of $38.33.

Read Our Latest Report on ZBIO

Zenas BioPharma Company Profile

(Get Free Report)

Zenas BioPharma, Inc is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.

See Also

Receive News & Ratings for Zenas BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zenas BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.